KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Interest & Investment Income (2018 - 2025)

Castle Biosciences' Interest & Investment Income history spans 7 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 14.12% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $11.8 million, down 8.86%, while the annual FY2025 figure was $11.8 million, 8.86% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $2.9 million at Castle Biosciences, up from $2.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.4 million in Q3 2024 and bottomed at $4000.0 in Q1 2021.
  • The 5-year median for Interest & Investment Income is $2.6 million (2023), against an average of $2.0 million.
  • The largest annual shift saw Interest & Investment Income crashed 98.66% in 2021 before it surged 13282.35% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $17000.0 in 2021, then soared by 13282.35% to $2.3 million in 2022, then skyrocketed by 37.1% to $3.1 million in 2023, then grew by 8.11% to $3.4 million in 2024, then fell by 14.12% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Interest & Investment Income are $2.9 million (Q4 2025), $2.8 million (Q3 2025), and $2.9 million (Q2 2025).